Calidi to Present RedTail Preclinical EEV Data, Plans IND Filing for CLD-401
Calidi Biotherapeutics will present RedTail platform preclinical data, including its engineered EEV virus’s selective tumor targeting and immune clearance avoidance, at the IOVC conference on April 28. The company expects to file an IND for lead candidate CLD-401 by year-end and is expanding RedTail for in situ T-cell engager expression.
1. IOVC Presentation on April 28
Calidi Biotherapeutics will deliver a keynote presentation at the International Oncolytic Virus Conference on April 28 in Reykjavik, showcasing data on its RedTail virotherapy platform and lead compound CLD-401 in systemic genetic medicine delivery.
2. RedTail Platform Mechanism
The RedTail platform uses an extracellular enveloped virus with CD55 overexpression to evade immune clearance, selectively replicate in tumor cells and remodel the tumor microenvironment while delivering high concentrations of therapeutic genetic payloads directly to tumor sites.
3. CLD-401 Lead Candidate and IND Timeline
CLD-401 is engineered to express an IL-15 superagonist within the tumor microenvironment to activate T and NK cells, with IND-enabling studies ongoing and a submission expected by the end of 2026 targeting non-small cell lung and head and neck cancers.
4. Platform Expansion for T-cell Engagers
Calidi is developing CLD-501, a RedTail virus expressing a TROP2-targeting T-cell engager alongside IL-15 SA, and is exploring additional solid tumor targets and strategic partnerships to accelerate clinical development and broaden its systemic genetic medicine approach.